JP2018527926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527926A5 JP2018527926A5 JP2018510419A JP2018510419A JP2018527926A5 JP 2018527926 A5 JP2018527926 A5 JP 2018527926A5 JP 2018510419 A JP2018510419 A JP 2018510419A JP 2018510419 A JP2018510419 A JP 2018510419A JP 2018527926 A5 JP2018527926 A5 JP 2018527926A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- substituted
- acid residue
- composition
- alanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710194807 Protective antigen Proteins 0.000 claims 33
- 125000000539 amino acid group Chemical group 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 235000004279 alanine Nutrition 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 230000000069 prophylactic effect Effects 0.000 claims 6
- 238000003259 recombinant expression Methods 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 239000004475 Arginine Chemical group 0.000 claims 4
- 235000009697 arginine Nutrition 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- 101000585552 Bacillus anthracis Protective antigen Proteins 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 235000013922 glutamic acid Nutrition 0.000 claims 3
- 239000004220 glutamic acid Chemical group 0.000 claims 3
- 235000004400 serine Nutrition 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims 2
- 241000193738 Bacillus anthracis Species 0.000 claims 2
- 101000954054 Bacillus anthracis Calmodulin-sensitive adenylate cyclase Proteins 0.000 claims 2
- 101001051090 Bacillus anthracis Lethal factor Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims 2
- 108010001014 Plasminogen Activators Proteins 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 229940065181 bacillus anthracis Drugs 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Chemical group SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000004554 glutamine Nutrition 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 2
- 229960002340 pentostatin Drugs 0.000 claims 2
- 229940127126 plasminogen activator Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 235000014393 valine Nutrition 0.000 claims 2
- 239000004474 valine Chemical group 0.000 claims 2
- 102100031325 Anthrax toxin receptor 2 Human genes 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 239000004471 Glycine Chemical group 0.000 claims 1
- 101000796085 Homo sapiens Anthrax toxin receptor 2 Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Chemical group 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 235000014705 isoleucine Nutrition 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229930182817 methionine Chemical group 0.000 claims 1
- 235000006109 methionine Nutrition 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 235000013930 proline Nutrition 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210771P | 2015-08-27 | 2015-08-27 | |
| US62/210,771 | 2015-08-27 | ||
| US201662323218P | 2016-04-15 | 2016-04-15 | |
| US62/323,218 | 2016-04-15 | ||
| PCT/US2016/048706 WO2017035359A1 (en) | 2015-08-27 | 2016-08-25 | Modified anthrax toxin protective antigen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018527926A JP2018527926A (ja) | 2018-09-27 |
| JP2018527926A5 true JP2018527926A5 (enExample) | 2019-10-03 |
| JP6865211B2 JP6865211B2 (ja) | 2021-04-28 |
Family
ID=56943920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510419A Active JP6865211B2 (ja) | 2015-08-27 | 2016-08-25 | 改変された炭疽毒素保護抗原 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10835593B2 (enExample) |
| EP (1) | EP3341393B1 (enExample) |
| JP (1) | JP6865211B2 (enExample) |
| KR (1) | KR20180073555A (enExample) |
| CN (1) | CN108350041A (enExample) |
| AU (1) | AU2016311429C1 (enExample) |
| WO (1) | WO2017035359A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311429C1 (en) | 2015-08-27 | 2021-10-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified anthrax toxin protective antigen |
| EP3880306A4 (en) | 2018-11-16 | 2023-01-25 | Rapa Therapeutics, LLC | ALS TREATMENT USING INDUCED REGULATORY T (IT REG) CELLS |
| CA3177588A1 (en) * | 2020-05-13 | 2021-11-18 | Daniel Harding FOWLER | Treatment or prevention of pro-inflammatory diseases or conditions using induced regulatory t (itreg) cells |
| JP7648075B2 (ja) * | 2020-11-27 | 2025-03-18 | 株式会社ダイセル | 融合タンパク質 |
| CN117343942B (zh) * | 2023-12-06 | 2024-02-13 | 南京市食品药品监督检验院 | 一种pagA重组蛋白及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1214340T3 (da) | 1999-09-24 | 2005-04-04 | Us Gov Health & Human Serv | Muterede antigen-proteiner, der beskytter mod anthrax-toxiner, og som specifikt målretter celler, der indeholder store mængder af celleoverflade-metalproteinaser eller plasminogenaktivator-receptorer |
| US7601351B1 (en) * | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| US7947289B2 (en) | 2004-02-09 | 2011-05-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multimeric protein toxins to target cells having multiple identifying characteristics |
| WO2008076939A2 (en) | 2006-12-14 | 2008-06-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculature |
| CN101215568B (zh) * | 2008-01-18 | 2010-06-23 | 畿晋庆三联（北京）生物技术有限公司 | 抗炭疽多肽及其应用与制备方法 |
| WO2014134187A1 (en) | 2013-02-26 | 2014-09-04 | The Regents Of The University Of California | Compositions and methods for the treatment of cancer |
| WO2014205187A1 (en) | 2013-06-20 | 2014-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor |
| AU2014324897A1 (en) * | 2013-09-25 | 2016-05-19 | Axcella Health Inc. | Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof |
| AU2016311429C1 (en) | 2015-08-27 | 2021-10-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified anthrax toxin protective antigen |
-
2016
- 2016-08-25 AU AU2016311429A patent/AU2016311429C1/en active Active
- 2016-08-25 CN CN201680062198.3A patent/CN108350041A/zh active Pending
- 2016-08-25 KR KR1020187008131A patent/KR20180073555A/ko not_active Ceased
- 2016-08-25 EP EP16767065.2A patent/EP3341393B1/en active Active
- 2016-08-25 WO PCT/US2016/048706 patent/WO2017035359A1/en not_active Ceased
- 2016-08-25 JP JP2018510419A patent/JP6865211B2/ja active Active
- 2016-08-25 US US15/755,341 patent/US10835593B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527926A5 (enExample) | ||
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| IL308807B2 (en) | Combination therapy for treating cancer | |
| MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012007850A (es) | Composiciones y metodo para tratar gliobastoma (gbm). | |
| TN2009000090A1 (en) | Prophylactic or therapeutic agent for canger | |
| JP2017018125A5 (enExample) | ||
| JP2019509037A5 (enExample) | ||
| IN2014KN01715A (enExample) | ||
| JP2017523184A5 (enExample) | ||
| JP2013172743A5 (enExample) | ||
| RU2015119517A (ru) | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 | |
| RU2009141595A (ru) | Пептиды тем8 и содержащие их вакцины | |
| CL2019003406A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| JP2012517799A5 (enExample) | ||
| JP2011528897A5 (enExample) | ||
| SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
| JP2018512124A5 (enExample) | ||
| IN2014DN09963A (enExample) | ||
| RU2010154101A (ru) | Пептиды эпитопов mybl2 и содержащие их вакцины |